Effects of the L- and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 3, 2001, Pages 450-459

  Hu, Wen Yang ^a   Fukuda, Noboru ^a,b   Su, Jin Zi ^a   Kanmatsuse, Katsuo ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Calcium antagonists; Cilnidipine; Growth factors; Spontaneously hypertensive rats; Vascular smooth muscle

Indexed keywords

ANGIOTENSIN; BASIC FIBROBLAST GROWTH FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; MESSENGER RNA; NIFEDIPINE; PHORBOL 13 ACETATE 12 MYRISTATE; PLATELET DERIVED GROWTH FACTOR AA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; DIHYDROPYRIDINES; DNA; FIBROBLAST GROWTH FACTOR 2; MUSCLE, SMOOTH, VASCULAR; NIFEDIPINE; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TETRADECANOYLPHORBOL ACETATE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0034888128     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200109000-00013     Document Type: Article

References (35)

1. Accelerated entry of aortic smooth muscle cells from spontaneously hypertensive rats into the S phase of the cell cycle
2. Vascular smooth muscle cell hyperresponsiveness to growth factors in hypertension
3. Molecular biology of vascular hypertrophy
4. Bunazosin hydrochloride inhibits exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats by suppressing the response to growth factors
5. Role of endogenous angiotensin II in the expression of growth factors and the cell cycle in vascular smooth muscle cells from SHR
6. Antisense oligodeoxynucleotide complementary to platelet-derived growth factor A-chain messenger RNA inhibits the arterial proliferation in spontaneously hypertensive rats without altering their blood pressures
7. Role of long-form PDGF A-chain in the growth of vascular smooth muscle cells from spontaneously hypertensive rats
8. Participation of proteolysis and transforming growth factor β1 activation in growth of cultured smooth muscle cells from spontaneously hypertensive rats
9. Inhibitory effect of an angiotensin II type I receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats
10. Stimulation of calcium entry is pre-requisite for DNA synthesis induced by platelet-derived growth factor in vascular smooth muscle cells
11. 2+ pool content is linked to control of cell growth
12. Critique of a biologic mechanism linking calcium antagonists to increased risk for cardiovascular events in diabetes
13. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation
14. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-κB in primary human vascular smooth muscle cells
15. An increase in adenylate cyclase activity precedes DNA synthesis in cultured vascular smooth muscle cells
16. Coupled reverse transcription-polymerase chain reaction (RT-PCR) as a sensitive and rapid method for isozyme genotyping
17. Quantitation of mRNA by the kinetic polymerase chain reaction assay: A tool for monitoring P-glycoprotein expression
18. Vascular protection with newer antihypertensive agents
19. Prevention of ischaemia-induced coronary vascular dysfunction
20. Calcium antagonists and atherosclerosis
21. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes
22. Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers
23. Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site
24. Current status of calcium antagonists in Japan
25. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor β1 expression determines growth response to angiotensin II
26. The synergistic effect of PDGF-AA and IGF-1 on VSMC proliferation might be explained by the differential activation of their intracellular signalling pathways
27. Production of angiotensin II by homogeneous cultures of vascular smooth muscle cells from spontaneously hypertensive rats
28. Contribution of synthetic phenotype on the enhanced angiotensin II-generating system in vascular smooth muscle cells from spontaneously hypertensive rats
29. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β
30. Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell culture
31. Vascular smooth muscle cells express distinct transforming growth factor-β receptor phenotypes as a function of cell density in culture
32. Characteristics and expression of transforming growth factor-β receptor subtypes on vascular smooth muscle cells from spontaneously hypertensive rats
33. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: Implications for vascular protection
34. Ca(2+)-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor
35. Transcriptional activation of low density lipoprotein receptor gene by angiotensin-converting enzyme inhibitors and Ca(2+)-channel blockers involves protein kinase C isoforms